<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36840">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01902121</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-178</org_study_id>
    <nct_id>NCT01902121</nct_id>
  </id_info>
  <brief_title>Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, Crossover Clinical Trial in Healthy Normal Volunteers to Evaluate the Bioequivalence of 30 U TI Inhalation Powder Delivered by Gen2 Inhaler Using One 30 U Cartridge Versus a Combination of 10 U and 20 U Cartridges</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, open-label, randomized,  crossover study in 36 healthy normal volunteers (HNVs)
      to evaluate the bioequivalence of TI Inhalation Powder delivered using the Gen2 Inhaler and
      administered as one 30 U cartridge versus a combination of one 10 U cartridge and one 20 U
      cartridge.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area-under-the-serum insulin concentration versus time curve (AUC0-240min</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 45, 60, 75, 90, 120,  150, 210 and 240 minutes post-TI dosing</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TI 30 units (10 unit + 20 unit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Technosphere速 Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TI 30 units (30 unit cartridge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Technosphere速 Insulin 30 units given as one 30 unit cartridge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere速  Insulin 10U + 20U</intervention_name>
    <description>Inhaled Insulin</description>
    <arm_group_label>TI 30 units (10 unit + 20 unit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere速  Insulin 30U</intervention_name>
    <description>Inhaled Insulin</description>
    <arm_group_label>TI 30 units (30 unit cartridge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 to 45 years, considered healthy based on screening physical
             examination, medical history, clinical chemistry, and urinalysis

          -  No smoking in the past 6 months (including cigarettes, cigars, and pipes)

          -  Urine cotinine testing &lt; 100 ng/mL

          -  Body mass index &lt; 32 kg/m2

          -  Completion of informed consent form

        Exclusion Criteria:

          -  FBG &gt; 100 mg/dL

          -  Clinically significant active or chronic illness

          -  History of asthma, chronic obstructive pulmonary disease (COPD), or any other
             clinically relevant chronic lung disease

          -  Respiratory tract infection within 4 weeks before screening and between the screening
             visit and dosing visit

          -  Subjects who are experiencing persistent or recurring cough, wheezing, bronchospasm,
             or dyspnea
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>July 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
